ICON Public (NASDAQ:ICLR) Now Covered by Analysts at TD Cowen

Equities researchers at TD Cowen initiated coverage on shares of ICON Public (NASDAQ:ICLR) in a research report issued on Wednesday, Briefing.com reports. The firm set an “outperform” rating and a $306.00 price target on the medical research company’s stock. TD Cowen’s price objective points to a potential upside of 18.94% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Mizuho lifted their price target on shares of ICON Public from $250.00 to $274.00 in a research report on Tuesday, July 11th. Deutsche Bank Aktiengesellschaft increased their price target on ICON Public from $280.00 to $300.00 in a research note on Friday, July 14th. Barclays upped their price objective on ICON Public from $250.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, July 28th. Finally, StockNews.com initiated coverage on ICON Public in a report on Thursday, August 17th. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $269.22.

ICON Public Trading Up 0.7 %

ICLR stock opened at $257.28 on Wednesday. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.48. The firm has a market cap of $21.14 billion, a P/E ratio of 41.70, a P/E/G ratio of 1.48 and a beta of 1.12. ICON Public has a 1-year low of $171.43 and a 1-year high of $268.07. The business’s 50 day moving average is $251.59 and its 200-day moving average is $227.45.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.92 by $0.04. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.02 billion. ICON Public had a net margin of 6.45% and a return on equity of 11.21%. Equities analysts anticipate that ICON Public will post 12.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Institutional investors have recently added to or reduced their stakes in the company. PGGM Investments increased its holdings in shares of ICON Public by 27.0% during the 4th quarter. PGGM Investments now owns 2,241 shares of the medical research company’s stock worth $435,000 after acquiring an additional 476 shares during the last quarter. Globeflex Capital L P boosted its holdings in shares of ICON Public by 0.8% during the 1st quarter. Globeflex Capital L P now owns 53,006 shares of the medical research company’s stock worth $11,322,000 after buying an additional 400 shares during the period. CIBC Private Wealth Group LLC grew its stake in ICON Public by 40.7% in the 4th quarter. CIBC Private Wealth Group LLC now owns 388,272 shares of the medical research company’s stock valued at $75,422,000 after buying an additional 112,232 shares during the last quarter. SYSTM Wealth Solutions LLC bought a new position in ICON Public in the 4th quarter valued at about $1,166,000. Finally, Russell Investments Group Ltd. lifted its position in ICON Public by 3.3% during the fourth quarter. Russell Investments Group Ltd. now owns 23,115 shares of the medical research company’s stock worth $4,490,000 after acquiring an additional 736 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.